The U.S Food and Drug Administration gave Thousand Oaks biotech giant Amgen the go-ahead to market its cholesterol drug Repatha to patients at risk of a heart attack or stroke. Shares for the company rose around 1 percent after the news, ending at $177.51 in after-hours trading. The drug brought in around $58 million for…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
